Skip to Content

American Psychiatric Association (APA)

Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the American Psychiatric Association (APA) and Society of Uniformed Services Psychiatrists. The APA is accredited by the ACCME to provide continuing medical education for physicians.

Designation

The APA designates this live activity for a maximum of 5 AMA PRA Category 1 Credit.™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician CME Certificates

At the conclusion of the conference, physician participants will be provided with an opportunity to claim hours of participation and receive an official CME certificate by completing the online CME conference evaluation.

  1. Go to http://apapsy.ch/amygdala
  2. Click ACCESS ACTIVITY and log in with your APA username and password or create a new account.
  3. Enter the Group ID: SUSP191
  4. On the Purchase page and click SUBMIT to proceed to the evaluation and certificate. Select “AMA PRA Category 1 Physician” as your certificate type.

You must claim your CME credit within 60 days of the conference. Certificates will not be issued after June 16, 2019. For customer support, please email apalms@psych.org.

Disclosure Information

Derrick A. Hamaoka, MD – Nothing to disclose
Eric Meyer II, MD – Nothing to disclose
Katy Pokorny – Nothing to disclose
Dennis S. Charney, MD – (See next page)
Anne Germain, PhD – CEO and Equity – Rehat, LLC, Consultant – Jazz Pharmaceuticals, Inc.
Jessica M. Gill, PhD, RN. – Nothing to disclose
James L. Griffith, MD – Nothing to disclose
Irwin Lucki, PhD – Consultant – Alkermes
COL Wendi Waits, MD – Capital Equity – Reimbursify
COL Christopher H. Warner, MD – Nothing to disclose
Kwang Choi, PhD – Nothing to disclose
Kelly L. Cozza, MD – Nothing to disclose
Iona M. Horotan-Enescu, MD – Nothing to disclose
Holly H. Mash, PhD – Nothing to disclose
David Mears, PhD – Nothing to disclose
James A. Naifeh, PhD – Nothing to disclose
Amy E. Steward, TSgt, USAF – Nothing to disclose
Robert J. Ursano, MD – Nothing to disclose
Gary H. Wynn, MD – Nothing to disclose

Meeting Objectives

At the end of this educational activity, the learner will be able to:

  • Understand how gpsychological stress alters brain function.
  • Understand psychobiological mechanisms of human resilience to stress.
  • You can train to be more resilient.
  • Implications for your own life.
  • Describe the importance of sleep as a biological force multiplier in psychological health, resilience, and readiness.
  • Explain the interaction between sleep and neural circuits underlying threat- and goal-oriented behaviors.
  • Detail the nature and impact of sleep-focused interventions on psychological health.
  • Describe the proteins that relate to PTSD as well as traumatic brain injury (TBI) symptoms.
  • Describe gene-activity profiles that relate to chronic PTSD symptoms.
  • Determine the long-term biological changes that relate to TBI and PTSD, which may have morbidity risks associated with them.
  • Conceptualize hope as a practice, i.e. “something you do” rather than “something you feel.”
  • Demonstrate rapid assessment of patients’ competencies for mobilizing hope in stressful circumstances.
  • Formulate and design interventions to mobilize hope when a patient is demoralized.
  • Show how empirical social psychology and social neuroscience can expand the scope and potency of psychotherapeutic interventions to mobilize hope and counter demoralization.
  • The state of research on developing rapid acting antidepressants for treatment-resistant depression.
  • The potential benefits of using ketamine in the treatment of mental health disorders.
  • The potential negatives of using ketamine in the treatment of mental health disorders.


Dennis S. Charney, MD

Ongoing Research Support P01HL131478 (PI: Fayad) 03/17/17-02/28/22 National Heart, Lung, and Blood Institute/NIH/DHHS Stress and atherosclerotic plaque macrophages – a systems biology approach Role: Co-Investigator N/A (PI: Bevilacqua) 07/15/18-07/15/20 Brain and Behavior Research Foundation Intranasal NPY

Role: Key Personnel, Co-Mentor 23629 (PI: Balchandani) 01/15/16-01/14/19 Brain and Behavior Research Foundation Development of 7T MRI protocol to establish imaging biomarkers for depression Role: Key Personnel, Mentor Completed Research Support (Past 3 Years K23MH099223 (PI: Iacoviello) 08/19/13 – 07/31/18 (Transferred) NIMH A Novel Cognitive Training Intervention for Depression
Role: Key Personnel, Mentor 2013098 (PI: Murrough) 07/01/13-06/30/17 (Ended Early) Doris Duke Charitable Foundation Ketamine Plus Lithium as a Novel Pharmacotherapeutic Strategy fin Treatment-Resistant Depression

Role: Key Personnel, Mentor K23MH094707 (PI: Murrough) 07/15/11-05/31/16 NIH Functional MRI Studies of Emotion IN Depression and Rapid Antidepressant Response

Named co-inventor US Patent No. 9,592,207 - Intranasal Administration of Ketamine to Treat Depression (Issued March 14, 2017); US Patent No. 9,539,220 - Methods for Treating Suicidal Ideation (Issued January 10, 2017) ; US Patent No. 8,785,500 - Intranasal Administration of Ketamine to Treat Depression (Issued July 22, 2014) ; US Patent No. 10,123,737 - Systems and Methods for Treating a Psychiatric Disorder (Issued November 13, 2018) ; US CON Patent Appl No. 16/189,059 – and related foreign patent applications - Systems and Methods for Treating a Psychiatric Disorder US Provisional Patent Appl No. 62/649,469 – Brain Plasticity Following Cognitive-Emotional Training ; US CON Patent Appl No. 14/974,576 and related foreign patent applications - Method for Treating Post Traumatic Stress Disorder (PTSD) ; US Serial No. 14/889,746 and a related foreign patent application - Treatment of Mood and Anxiety Disorders ; US CON Patent Appl Nos. 15/379,013 and 15/417,689 - Intranasal Administration of Ketamine to Treat Depression.